We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Monthly Opioid Abuse Treatment Wins FDA Advisory Committee OK
Monthly Opioid Abuse Treatment Wins FDA Advisory Committee OK
FDA advisory committee members overwhelmingly recommended approval of Indivior’s RBP-6000, an extended-release reformulation of buprenorphine for the treatment of opioid abuse.